Private and public hospitals treated very different inflammatory bowel disease populations in New York City
Patients with inflammatory bowel disease did not arrive at private nonprofit and public hospitals on equal footing. In a retrospective New York City cohort, the two settings served groups that differed sharply in race, ethnicity, insurance status, and housing stability before any outcome comparison was even applied.
The study included 418 adults with established care for Crohn’s disease or ulcerative colitis, split evenly between the two hospitals. Researchers compared patient demographics, disease features, healthcare use, treatment patterns, and clinical outcomes across settings, then used linear mixed and logistic models to account for factors that differed between groups. The design matters because hospital type often stands in for a much larger social and clinical story: access to specialty care, continuity of treatment, medication affordability, and the reliability of follow-up all shape the course of chronic intestinal inflammation.
The baseline separation was unmistakable. Patients treated at the private nonprofit hospital were more likely to be White, non-Hispanic, and privately insured, while public hospital patients were more likely to face housing instability. Each of those characteristics can influence the trajectory of IBD in ways that extend beyond the gut itself. Medication adherence can falter when housing is unstable. Clinic attendance becomes harder when transportation, work schedules, or insurance gaps disrupt care. Even when the underlying inflammatory burden is similar, the environment surrounding treatment can push outcomes in different directions.
Social risk shaped the cohort before treatment decisions were even analyzed.
Social determinants framed the comparison before outcomes entered the picture
IBD is a chronic immune-mediated disease, but the biology of inflammation does not unfold in isolation from the biology of daily life. Access to biologic therapy, timely imaging, endoscopy, and colorectal surgery consults often depends on insurance coverage and stable contact with a care team. Patients who move between temporary housing situations or struggle with inconsistent access to medications can experience more flares, more emergency care, and more fragmented follow-up. In that setting, hospital affiliation may capture more than institutional preference; it may reflect the social infrastructure available to the patient.
The study’s modeling strategy attempted to separate those effects statistically. By using mixed and logistic models and controlling for factors that differed between the groups, the investigators tried to isolate whether the care setting itself tracked with measurable differences in utilization and outcomes. That approach is appropriate in a real-world cohort where patient mix is unequal, because crude comparisons would otherwise risk blaming the hospital for differences rooted in structural inequity. Even so, statistical adjustment can only do so much when the underlying populations are so different at baseline.
What gives the analysis clinical relevance is not just the presence of disparities, but the fact that they cluster around variables known to alter chronic disease control. Private insurance can ease access to specialty medications and elective procedures. Housing instability can undermine the kind of stable longitudinal care that IBD requires. Race and ethnicity are not biological explanations, but in the United States they often mark exposure to unequal access, differential referral pathways, and longstanding gaps in care delivery. In a disease where remission depends on sustained therapy and careful monitoring, those gaps can become clinically visible quickly.
The hospital setting may reflect unequal access to the same disease tools
For gastroenterologists, the practical question is not whether IBD outcomes are influenced by social determinants; they are. The more relevant issue is how much hospital type acts as a proxy for those determinants and whether standard care pathways are robust enough to blunt them. A private nonprofit hospital may see patients with greater financial stability and more reliable coverage for advanced therapies. A public hospital may absorb a larger share of patients with unstable housing, limited insurance, and broader barriers to outpatient continuity. The disease process is the same, but the scaffolding around treatment is not.
The cohort design makes that contrast visible, even in the limited abstracted data available here. With 209 patients from each hospital, the sample was balanced by site, which supports a direct institutional comparison. The demographic and insurance differences were strong enough to reach statistical significance, with the abstract reporting P values of .0005 for White race, non-Hispanic ethnicity, and private insurance. Housing instability also differed between groups. Those are not peripheral details. They are the context in which flare management, biologic initiation, and follow-up adherence either succeed or fail.
The abstract does not provide the full outcome detail in the excerpt available here, so the most defensible interpretation is narrower: the study documents a structurally unequal patient mix between private and public hospital IBD populations and uses adjusted models to evaluate whether that mix translates into different outcomes. In a specialty that relies on continuous surveillance and escalating therapy when needed, that kind of disparity can shape the timing of remission, hospitalization, and long-term disease control.
For clinicians, the message is immediate even without the final outcome tables. A hospital is not just a place where IBD is treated; it is part of the mechanism by which treatment either reaches the patient or falls short. When insurance, housing stability, and race cluster by site, the downstream consequences can appear in utilization patterns, medication access, and the ability to sustain remission over time.